Growing Concern: What Women Should Know About Mycoplasma genitalium (M. genitalium)

Mycoplasma genitalium (M. genitalium, often abbreviated Mgen) has emerged over the past decade as an important sexually transmitted bacterial pathogen affecting the urogenital tract. Although it was first described in the early 1980s, improvements in nucleic acid testing and growing awareness have led to increased detection. For clinicians and women seeking informed guidance, understanding the organism’s clinical presentation, potential reproductive health consequences, current diagnostic and treatment challenges, and practical prevention strategies is essential.

This article summarizes current knowledge about M. genitalium with a clinical focus, highlights areas of uncertainty, and provides practical recommendations for women and clinicians. Sources include guidance and educational resources from major medical institutions and public health authorities (American College of Obstetricians and Gynecologists [ACOG], National Institutes of Health [NIH], Mayo Clinic, Cleveland Clinic, and public health agencies).

Understanding M. genitalium: organism, transmission, and epidemiology

M. genitalium is a small, cell-wall–free bacterium that preferentially infects epithelial cells of the urogenital tract. It is transmitted primarily through sexual contact involving mucosal exposure. Routes of transmission include vaginal and possibly oral or anal sexual activity; the highest risk is associated with unprotected genital contact and multiple sexual partners.

Epidemiology and prevalence:

Prevalence estimates vary by population and geography. In general population samples, prevalence among sexually active women is low (often reported as 1–3%), but rates are substantially higher in clinical populations seeking care for urogenital symptoms, among those attending STI clinics, and among individuals with new or multiple sexual partners. Surveillance has documented rising detection rates in many regions, in part because of increased molecular testing availability (nucleic acid amplification tests, NAATs).
M. genitalium prevalence and resistance patterns are dynamic. Macrolide resistance (to drugs such as azithromycin) has increased globally, which complicates empiric management strategies (ACOG; NIH). (See professional references at the end.)

Clinical presentation in women: often silent, sometimes consequential

One of the defining clinical features of M. genitalium is that infection is frequently asymptomatic, particularly in women. This silent course contributes to underdiagnosis and potential ongoing transmission.

Symptomatic presentations (when present) may include:

Cervicitis: inflammation of the cervix, sometimes with mucopurulent discharge, postcoital spotting, or abnormal cervical exam findings.
Urethritis: dysuria or urinary frequency may occur, although findings can overlap with urinary tract infection.
Pelvic inflammatory disease (PID): ascent of infection into the upper genital tract can produce endometritis, salpingitis or tubo-ovarian involvement manifesting with pelvic pain, fever, and adnexal tenderness.
Abnormal vaginal bleeding, pelvic discomfort, and persistent or recurrent vaginal discharge.

Timing and natural history:

Symptoms, when they develop, may appear weeks to months after exposure. The organism can persist for months if untreated and, in some cases, for years.
Because symptoms are often absent or nonspecific, many infections are identified only after screening (in targeted settings) or evaluation for persistent genitourinary symptoms.

Potential reproductive and obstetric consequences

M. genitalium has been linked in observational studies to adverse reproductive outcomes, although some associations remain incompletely defined and subject to ongoing research.

Documented and potential complications include:

Pelvic inflammatory disease (PID): Several studies associate M. genitalium with PID. PID increases risks of tubal scarring, infertility, chronic pelvic pain, and ectopic pregnancy.
Infertility and ectopic pregnancy: By contributing to tubal inflammation and scarring, untreated or recurrent upper genital tract infection may impair fertility and increase ectopic pregnancy risk.
Pregnancy outcomes: Some research suggests associations between M. genitalium and adverse outcomes such as preterm birth and spontaneous abortion; however, evidence is not as robust as for other pathogens (for example, Chlamydia trachomatis) and further study is needed. Management of M. genitalium in pregnancy requires special consideration because some effective agents have safety concerns in pregnancy.
HIV susceptibility: As with other STIs that cause mucosal inflammation, M. genitalium infection may increase susceptibility to HIV acquisition and transmission, although the strength of this association varies by study.

Clinical implication: Because the organism can ascend and cause upper genital tract inflammation, clinicians should consider M. genitalium as a possible etiologic agent in women with cervicitis, persistent urethritis, or PID, particularly when routine STI tests (chlamydia/gonorrhea) are negative.

(References: ACOG, NIH/NIAID, Mayo Clinic)

Diagnosis: NAAT is the diagnostic standard; resistance testing increasingly important

Laboratory testing is required to confirm M. genitalium infection. Culture is technically difficult and impractical for routine clinical use; nucleic acid amplification tests (NAATs) are the recommended diagnostic modality.

Key diagnostic points:

Test types and specimens: For women, clinician-collected or self-collected vaginal swabs are commonly used and generally provide good sensitivity. Endocervical swabs and urine specimens can be used in some circumstances, but vaginal swabs are frequently the preferred sample type in women. NAATs detect bacterial DNA or RNA.
Availability: NAAT availability has expanded, but not all laboratories or clinics offer routine testing. Some commercial assays also provide genotypic resistance testing (detection of macrolide resistance–associated mutations), which can guide therapy.
Indications for testing: Current practice commonly supports testing symptomatic women with cervicitis or persistent urethritis and women with PID when routine testing does not explain symptoms. Some guidelines recommend testing women with persistent or recurrent symptoms after treatment for other STIs. Routine population-wide screening is not universally recommended; testing should be guided by clinical presentation, risk factors, and local protocols (ACOG; CDC).
Resistance testing: Detection of macrolide-resistance mutations (in the 23S rRNA gene) is clinically useful because it predicts likely azithromycin treatment failure. Resistance-guided therapy (where available) improves treatment success and reduces unnecessary exposure to ineffective antibiotics.

Limitations:

False negatives can occur if the organism load is low or if suboptimal specimens are obtained.
Not all NAATs include resistance mutation analysis; clinicians should be aware whether local testing provides resistance information.

(References: NIH/NIAID, Mayo Clinic, ACOG)

Treatment: antibiotic choices, resistance concerns, and follow-up

Treating M. genitalium has become more challenging because of rising antimicrobial resistance, particularly to macrolides. Management should balance efficacy, local resistance patterns, patient-specific factors (including pregnancy), and antimicrobial stewardship.

General therapeutic principles:

Agents with activity: Historically, macrolides (azithromycin) were the first-line therapy, but increasing macrolide resistance has led to declining cure rates. Tetracyclines (doxycycline) have modest efficacy but are often used as an initial agent to reduce organism burden. Fluoroquinolones (moxifloxacin) have high efficacy for macrolide-resistant infections but carry safety considerations.
Resistance-guided therapy: When available, testing for macrolide-resistance mutations should guide therapy. If a macrolide-susceptible strain is identified, macrolide-based regimens may be used; if resistance mutations are present, fluoroquinolone therapy is generally recommended.
Typical regimens used in many clinical protocols (regimens and durations are subject to guideline updates and regional variation):
Doxycycline 100 mg twice daily for 7 days — frequently used as initial therapy in some resistance-guided approaches because it lowers bacterial load but has limited cure rates as monotherapy.
Azithromycin (macrolide): extended-dose regimens (total 1.5 g given as 1 g on day 1 followed by 500 mg daily for 2–5 days in some protocols) have been used to reduce resistance selection compared with single-dose azithromycin; however, failure rates are higher when macrolide resistance is present.
Moxifloxacin 400 mg once daily for 7–14 days — widely used and effective for macrolide-resistant disease but associated with risks (e.g., QT prolongation, tendonitis, central nervous system effects). Use caution in patients with cardiac conduction abnormalities and in pregnancy, where it is contraindicated.
Test-of-cure: Repeat NAAT to confirm eradication is recommended in most settings, typically about 3–4 weeks after completion of therapy, particularly when using macrolide-based regimens or when resistance is suspected. Early test-of-cure reduces the risk of ongoing transmission and allows prompt retreatment if necessary.
Partner management: Sexual partners should be evaluated and managed according to local STI control practices. Abstinence from sexual activity until completion of therapy and confirmation of cure minimizes reinfection risk.

Special situations:

Pregnancy: Treatment is challenging because moxifloxacin is contraindicated in pregnancy, and macrolide resistance reduces the effectiveness of azithromycin. Treatment decisions in pregnancy require obstetric consultation and consideration of risks and benefits. Some experts recommend azithromycin when necessary, but resistance must be addressed — specialist input is often required.
Persistent or recurrent infection: If symptoms or NAAT positivity persist after first-line therapy, clinicians should perform resistance testing (if not already done) and consider alternative agents (e.g., moxifloxacin for macrolide resistance). Multidrug-resistant M. genitalium is an emerging problem, and consultation with infectious diseases specialists may be warranted. In certain regions, other agents such as pristinamycin (not widely available in all countries) have been used for multidrug-resistant infections.

Clinical caution:

Antibiotic regimens and specific dosing vary by guideline and by country. Clinicians should consult current ACOG, CDC, local public health, and infectious disease guidance when making treatment decisions.
Because of antimicrobial-resistance concerns, empiric treatment choices should be carefully considered; resistance-guided approaches are preferred where available.

(References: ACOG, NIH/NIAID, Mayo Clinic, Cleveland Clinic)

Screening recommendations and who should be tested

Routine population-wide screening for M. genitalium is not universally recommended. Testing strategies are generally targeted:

Consider testing for women with signs and symptoms of cervicitis, urethritis, or PID when other causes are not identified.
Test women with persistent or recurrent genitourinary symptoms after empiric therapy for more common causes (for example, chlamydia) or after failure of first-line therapy.
Some clinical settings with high-risk populations (e.g., STI clinics, individuals with multiple partners, sex workers) may consider targeted testing programs, depending on local epidemiology and resources.
Asymptomatic screening in pregnant women is not routinely recommended; testing and treatment decisions during pregnancy should be individualized and involve obstetric care.

Clinicians should follow national and local guidelines for testing indications, specimen collection, and laboratory selection.

(References: ACOG, NIH, CDC)

Prevention strategies: practical steps women can take

While no vaccine exists for M. genitalium, several practical measures can reduce the risk of acquisition and transmission:

Consistent barrier protection: Correct and consistent use of barrier methods (e.g., condoms, when used properly and consistently) reduces the likelihood of transmission of many STIs, including M. genitalium, although protection is not absolute.
Limit number of sexual partners and choose partners carefully: Mutual monogamy with an uninfected partner reduces exposure risk.
Communicate with partners and seek prompt evaluation: Timely evaluation and treatment of symptomatic partners reduce reinfection risk.
Avoid behaviors that increase vulnerability: Practices such as douching can alter the vaginal microbiome and may increase susceptibility to infection and adverse reproductive outcomes.
Regular sexual health check-ups: For people with higher-risk exposures, periodic evaluation at sexual health clinics or by primary care/gynecologic providers allows early detection and management of STIs.
Abstain from sexual activity until treatment is complete and infection is resolved: This reduces risk of transmission and reinfection.

Education and open communication with healthcare providers about symptoms and risk behaviors remain key to prevention.

(References: Mayo Clinic, Cleveland Clinic, ACOG)

Special populations: pregnancy, adolescents, and considerations

Pregnant individuals:

M. genitalium infection in pregnancy has been associated in some studies with adverse outcomes (preterm birth), but evidence is mixed. Treatment options in pregnancy are limited by safety concerns with some effective agents.
Management decisions should involve obstetric care and may require specialist consultation. Empiric treatment decisions must weigh potential maternal benefits against fetal risks.

Adolescents:

Adolescents should receive confidential, age-appropriate sexual health counseling, including discussion of STI risks, prevention strategies, and testing when indicated.
Clinicians should provide nonjudgmental care, ensure privacy protections, and engage caregivers as appropriate per laws and best practices.

Other considerations:

Individuals with immunocompromising conditions may have atypical presentations and require individualized care.
Cultural, socioeconomic, and access barriers affect care-seeking behavior and access to testing; clinicians should be mindful of these factors.

(References: ACOG, NIH)

Public health implications and research priorities

M. genitalium represents a growing public health concern because:

The organism causes reproductive tract disease with potential long-term sequelae.
Rising antimicrobial resistance reduces treatment options and complicates control measures.
Diagnostic and resistance testing availability remains variable, limiting widespread resistance-guided approaches.

Research priorities include:

Development of point-of-care NAATs and rapid resistance assays to support timely, targeted therapy.
New antimicrobial agents or combination regimens effective against resistant strains and safe in pregnancy.
Larger, prospective studies to clarify the organism’s role in adverse pregnancy and reproductive outcomes.
Surveillance programs to monitor prevalence and resistance trends and to guide treatment recommendations.

Public health responses must balance clinical needs, antimicrobial stewardship, and access to diagnostics.

(References: NIH/NIAID, public health literature)

Practical clinical recommendations for women

If you are a woman seeking to minimize risk or obtain evaluation:

Seek care if you have persistent pelvic pain, abnormal bleeding, unusual discharge, dysuria not explained by urinary tract infection, or if you have been notified by a partner of an STI exposure.
Tell your provider about recent sexual partners, condom use, pregnancy plans, and any prior STI diagnoses or treatments.
Ask about the availability of NAAT testing for M. genitalium and whether resistance testing is performed. If resistance testing is not available, clinicians may recommend empiric strategies based on local resistance patterns and clinical presentation.
If you are treated for M. genitalium, follow instructions regarding completion of therapy, partner notification and treatment, abstaining from sexual activity until cleared, and returning for a test-of-cure as recommended (typically about 3–4 weeks after treatment completion).
If you become pregnant or are planning pregnancy and have been diagnosed with M. genitalium, seek specialty consultation to weigh risks, benefits and safe therapeutic options.

Frequently asked questions (FAQs)

Can M. genitalium be cured?
Yes, most infections can be eradicated with appropriate antimicrobial therapy. However, rising antimicrobial resistance has reduced cure rates for some regimens. Resistance-guided therapy and follow-up testing improve cure likelihood.

Does M. genitalium affect fertility?
M. genitalium has been associated with pelvic inflammatory disease and, consequently, with potential risks to fertility (e.g., tubal scarring). Early diagnosis and treatment of upper genital tract infection help reduce this risk.

Should I get screened routinely for M. genitalium?
Routine screening is not universally recommended for asymptomatic women. Testing is indicated for symptomatic individuals (cervicitis, urethritis, PID) and in certain high-risk settings or for persistent symptoms after treatment. Follow local guideline recommendations.

Is there a vaccine?
No vaccine exists for M. genitalium. Prevention relies on behavioral measures, barrier protection, partner management, and screening when indicated.

What if my infection is resistant?
If macrolide resistance is detected or suspected, alternative agents such as moxifloxacin are commonly used after considering risks and contraindications. Multidrug-resistant cases may require specialist infectious disease consultation and access to less common agents.

(References: ACOG, NIH, Mayo Clinic)

Conclusion

M. genitalium is an emerging sexually transmitted bacterial pathogen with important implications for women’s reproductive health. Its often-asymptomatic nature, potential to cause cervicitis and pelvic inflammatory disease, and the increasing prevalence of antimicrobial resistance create diagnostic and therapeutic challenges. Women and clinicians should be alert to symptoms suggestive of infection, advocate for appropriate NAAT and resistance testing when indicated, and use evidence-based, resistance-informed treatment strategies. Prevention remains focused on barrier protection, reduction of partner exposure, prompt evaluation of symptoms, and partner management. As surveillance, diagnostic capacity, and therapeutic options evolve, ongoing research and public health efforts will be critical to control the impact of M. genitalium.

References and resources

American College of Obstetricians and Gynecologists (ACOG) — patient and clinician guidance on sexually transmitted infections: https://www.acog.org
National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) — information on Mycoplasma genitalium: https://www.niaid.nih.gov/diseases-conditions/mycoplasma-genitalium
Mayo Clinic — clinical overview of Mycoplasma genitalium, diagnosis and treatment considerations: https://www.mayoclinic.org
Cleveland Clinic — patient education on Mycoplasma genitalium and sexually transmitted infections: https://my.clevelandclinic.org
Centers for Disease Control and Prevention (CDC) — Sexually transmitted infections clinical resources (including guidance relevant to M. genitalium): https://www.cdc.gov/std

Note: Clinical practice and recommended antibiotic regimens evolve as new evidence emerges. Patients should consult their healthcare provider for individualized diagnosis and treatment.